Clinical stage I-IV resectable solid tumors planned to be treated with definitive therapy
Conditions
Interventions
None listed
Sponsors
National Cancer Center Hospital East
iTMS,Inc
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all eligibility criteria and none of the exclusion criteria will be enrolled in this study. 1)18 years-old <= 2)Diagnosed with a resectable solid tumor of clinical stage I-IV. 3)Planned to undergo curative-intent treatment, including curative surgical resection or definitive chemotherapy/chemoradiotherapy.*1 4)Availability of tumor tissue specimens for pathological evaluation.*2 5)ECOG Performance Status (PS) of 0 or 1. 6)Written informed consent. *1 Patients scheduled for curative resection are eligible even if they undergo preoperative chemoradiotherapy. *2 A tissue biopsy prior to treatment initiation is preferred; however, surgical specimens are acceptable in cases undergoing surgery.
Exclusion criteria
Exclusion criteria: 1)Active multiple primary cancers 2)Pregnant 3)History of other malignancies within 3 years prior to enrollment 4)Severe comorbid diseases (e.g., poorly controlled diabetes, infections, symptomatic interstitial pneumonia or pulmonary fibrosis) 5)Other reasons deemed inappropriate for this study by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Association between molecular profiles, including genetic alterations in tumor tissue and MRD, and relapse and prognosis | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between molecular profiles, including genetic alterations in tumor tissue and MRD, and their relationship with clinico pathological factors. | — |
Countries
Japan
Contacts
Public ContactTadayoshi Hashimoto
National Cancer Center Hospital East Department of Drug Development Promotion
Outcome results
None listed